XML 48 R35.htm IDEA: XBRL DOCUMENT v3.3.1.900

Collaborative Agreements (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Contract Research And Development [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Other Research and Development Expense	$ 10.0	$ 12.9
Abbott Products, Inc. [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement, Termination Date	Mar. 29, 2012
Collaborative Arrangement, Rights and Obligations	All obligations under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual 1% royalty on net sales.
Collaborative Arrangement, Royalties, Maximum Amount	$ 1.0
Collaborative Arrangement, Royalties, Percentage of Reduction	50.00%

X

- Definition

This element represents the maximum amount of royalties under collaborative arrangements.

+ References

No definition available.

+ Details

Name:	lpcn_CollaborativeArrangementRoyaltiesMaximumAmount
Namespace Prefix:	lpcn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

This element represents the percentage of reduction of royalties under collaborative arrangements, If generic versions of any such product are introduced.

+ References

No definition available.

+ Details

Name:	lpcn_CollaborativeArrangementRoyaltiesPercentageOfReduction
Namespace Prefix:	lpcn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

This element represents that, agreement termination date under collaborative arrangements.

+ References

No definition available.

+ Details

Name:	lpcn_CollaborativeArrangementTerminationDate
Namespace Prefix:	lpcn_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Description of rights and obligations under the collaborative arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_CollaborativeArrangementRightsAndObligations
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of other research and development expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=lpcn_ContractResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=lpcn_AbbottProductsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: